New drug combo shows promise for Tough-to-Treat breast cancer
NCT ID NCT05445908
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups based on cancer type (triple-negative or HR+/HER2-) and randomly assigned to get SKB264 alone or with KL-A167.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SKB264 (a drug) and KL-A167 (another drug)
What this could lead to
If successful, this could provide a new treatment option for advanced HER2-negative breast cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early phase 2 trial with a small number of participants, so results may not apply to all patients. Side effects from the drugs could be serious, and the combination may not work better than SKB264 alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE/HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Culmerciclib Breast Cancer Trial (NCT07666555)
- Young HOPE Trial: Response-Guided Therapy for Br NCT07671885
- Novartis Radioligand Therapy Trial for Solid Tum NCT07660055
- TQB3616 for HR+/HER2- Breast Cancer Trial NCT05780567
- HLX97 for Advanced Solid Tumors - Trial NCT07480681
- Neoadjuvant QL1706 + Chemo for HR+/HER2- Breast NCT07396324
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China